Your browser is no longer supported. Please, upgrade your browser.
AGLE [NASD]
Aeglea BioTherapeutics, Inc.
Index- P/E- EPS (ttm)-1.61 Insider Own2.51% Shs Outstand65.07M Perf Week-11.45%
Market Cap347.49M Forward P/E- EPS next Y-1.10 Insider Trans0.00% Shs Float46.71M Perf Month-8.69%
Income-80.90M PEG- EPS next Q-0.17 Inst Own92.50% Short Float4.67% Perf Quarter-8.69%
Sales- P/S- EPS this Y38.10% Inst Trans0.05% Short Ratio12.68 Perf Half Y-17.76%
Book/sh2.15 P/B3.27 EPS next Y9.10% ROA-58.30% Target Price- Perf Year-14.67%
Cash/sh2.96 P/C2.38 EPS next 5Y- ROE-68.70% 52W Range6.20 - 11.38 Perf YTD-10.55%
Dividend- P/FCF- EPS past 5Y-8.50% ROI- 52W High-34.97% Beta1.66
Dividend %- Quick Ratio9.10 Sales past 5Y- Gross Margin- 52W Low19.35% ATR0.44
Employees90 Current Ratio9.10 Sales Q/Q- Oper. Margin- RSI (14)45.87 Volatility5.76% 5.99%
OptionableYes Debt/Eq0.00 EPS Q/Q46.40% Profit Margin- Rel Volume0.47 Prev Close7.04
ShortableYes LT Debt/Eq0.00 EarningsMar 18 BMO Payout- Avg Volume172.15K Price7.40
Recom2.10 SMA20-4.16% SMA50-4.78% SMA200-4.29% Volume81,609 Change5.11%
May-04-20Initiated Piper Sandler Overweight $12
Mar-21-19Initiated JP Morgan Overweight $14
Sep-04-18Downgrade Wells Fargo Outperform → Market Perform
Apr-24-18Initiated Evercore ISI Outperform $37
Mar-14-18Reiterated Needham Buy $8 → $12
May-10-21 08:30AM  
May-06-21 08:30AM  
May-03-21 08:30AM  
Apr-01-21 04:30PM  
Mar-22-21 08:30AM  
Mar-18-21 08:30AM  
Feb-24-21 04:30PM  
Feb-18-21 01:45AM  
Feb-08-21 10:11AM  
Feb-03-21 04:30PM  
Jan-04-21 04:30PM  
Dec-30-20 12:00PM  
Dec-18-20 08:28PM  
Dec-17-20 04:05PM  
Dec-01-20 07:30AM  
Nov-24-20 04:40PM  
Nov-17-20 04:30PM  
Nov-10-20 05:40AM  
Nov-05-20 08:30AM  
Nov-03-20 08:44AM  
Oct-26-20 08:30AM  
Oct-13-20 12:35PM  
Oct-05-20 04:30PM  
Sep-11-20 06:39AM  
Sep-02-20 04:05PM  
Aug-25-20 08:40AM  
Aug-18-20 04:05PM  
Aug-10-20 08:30AM  
Jul-13-20 09:28AM  
Jun-30-20 11:25PM  
Jun-29-20 12:00PM  
Jun-26-20 11:30AM  
Jun-23-20 08:47AM  
Jun-10-20 11:30AM  
Jun-08-20 09:03AM  
Jun-04-20 11:17AM  
Jun-01-20 04:05PM  
May-29-20 11:49AM  
May-28-20 04:10PM  
May-27-20 08:43AM  
May-26-20 08:30AM  
May-21-20 11:30AM  
May-20-20 08:56AM  
May-19-20 07:26PM  
10:10AM  
08:30AM  
May-07-20 08:41AM  
08:30AM  
May-06-20 09:31AM  
06:19AM  
May-05-20 12:00PM  
Apr-30-20 04:05PM  
Apr-28-20 09:07AM  
Apr-27-20 04:01PM  
Apr-08-20 07:30AM  
Mar-29-20 08:31AM  
Feb-24-20 07:30AM  
Feb-13-20 05:37AM  
Jan-13-20 07:00AM  
Jan-08-20 05:11AM  
Jan-06-20 04:05PM  
Dec-12-19 07:08PM  
Dec-03-19 05:22AM  
Nov-26-19 08:30AM  
Nov-06-19 08:30AM  
Nov-04-19 08:30AM  
Oct-10-19 08:54AM  
Sep-04-19 11:22AM  
Sep-03-19 06:00AM  
Aug-29-19 08:30AM  
Aug-06-19 08:00AM  
Jul-25-19 07:21AM  
Jul-24-19 04:05PM  
Jul-17-19 03:47PM  
Jun-14-19 08:15PM  
Jun-11-19 07:37PM  
Jun-03-19 08:30AM  
May-30-19 08:30AM  
May-24-19 10:30AM  
May-22-19 07:15PM  
May-07-19 07:51AM  
07:45AM  
Apr-27-19 09:11AM  
Apr-08-19 10:30AM  
Apr-07-19 07:15PM  
Apr-01-19 08:00AM  
Mar-28-19 08:30AM  
Mar-12-19 05:41PM  
Mar-08-19 12:44AM  
Mar-07-19 04:05PM  
Mar-06-19 01:41PM  
Feb-28-19 08:00AM  
Feb-07-19 09:12AM  
Feb-06-19 12:15AM  
Feb-05-19 05:15PM  
Jan-29-19 09:57AM  
Jan-02-19 09:09AM  
Dec-23-18 07:52AM  
Dec-14-18 12:59PM  
Dec-11-18 04:05PM  
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.